What You Should Know:
– Medtronic (NYSE:MDT), a global leader in healthcare technology, announced it has received CE Mark approval for its groundbreaking BrainSense™ Adaptive deep brain stimulation (aDBS) technology in the European Union and the United Kingdom.
– The CE approval marks a significant advancement in personalized Parkinson’s disease treatment, offering patients in Europe access to a more responsive and tailored therapy.
BrainSense™ aDBS: A New Era of Personalized Parkinson’s Treatment
For three decades, deep brain stimulation (DBS) has been a valuable tool for managing Parkinson’s disease symptoms. This technology involves implanting a device that sends electrical signals to specific brain regions to disrupt abnormal nerve signals that cause tremors and other movement difficulties.
BrainSense™ aDBS takes this therapy to a new level by dynamically adjusting stimulation based on each patient’s unique brain activity. This personalized approach allows for more precise and effective treatment, potentially improving motor control and quality of life for individuals with Parkinson’s disease.
Clinical Validation and Research
The ADAPT-PD trial, the largest and longest assessment of aDBS to date, has demonstrated the clinical benefits of this technology. The study, conducted in both clinical and home settings, evaluated the safety and effectiveness of aDBS compared to conventional continuous DBS.
Expanding Access to Innovative Therapies
Medtronic’s BrainSense™ aDBS technology is expected to be available in Europe in early 2025. This approval brings hope to millions of people living with Parkinson’s disease in Europe, offering a new era of personalized and adaptive treatment.
“BrainSense™ technology† is at the center of personalizing DBS therapy, and we are advancing this capability through innovation that builds on our sensing-enabled DBS platform,” said Paolo Di Vincenzo, president of the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “From improved precision for contact selection to automatically adjusting DBS therapy, these milestones mark significant advancements in our ability to customize care for people with Parkinson’s, and we’re just getting started. The mission is to impact and improve many more lives with Medtronic DBS therapy.”
